Diagnostic and prognostic value of CSF neurofilaments in a cohort of patients with motor neuron disease: A cross-sectional study.
Aged
Amyotrophic Lateral Sclerosis
/ cerebrospinal fluid
Biomarkers
/ cerebrospinal fluid
Case-Control Studies
Cerebrospinal Fluid
/ metabolism
Cross-Sectional Studies
Disease Progression
Female
Follow-Up Studies
Humans
Intermediate Filaments
/ metabolism
Male
Motor Neuron Disease
/ cerebrospinal fluid
Neurofilament Proteins
/ cerebrospinal fluid
Phosphorylation
Prognosis
amyotrophic lateral sclerosis
biomarkers
cerebrospinal fluid
motor neuron disease
neurofilaments
spinal muscular atrophy
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
08
12
2020
received:
21
10
2020
accepted:
14
12
2020
pubmed:
21
2
2021
medline:
23
9
2021
entrez:
20
2
2021
Statut:
ppublish
Résumé
Motor neuron disease (MND) is a rare group of disorders characterized by degeneration of motor neurons (MNs). The most common form of MND, amyotrophic lateral sclerosis (ALS), is an incurable disease with a variable rate of progression. The search of robust biomarkers able to discriminate among different ALS forms is paramount to properly stratify patients, and to identify those who could most likely benefit from experimental therapies. Phosphorylated-neurofilament heavy chain (p-NfH) and neurofilament light chain (NfL) are neuron-specific components of the cytoskeleton and may represent reliable markers of neuronal injury in neurological disorders. In this study, we described our cohort of ALS patients in order to investigate whether and how cerebrospinal fluid (CSF) p-NfH and NfL levels may reflect progression rate, MN involvement and the extent of neurodegeneration. CSF p-NfH and NfL were significantly increased in ALS compared with healthy and disease controls, including patients with other forms of MND, and were higher in patients with more aggressive disease course, reflecting progression rate. We also evaluated neurofilament diagnostic accuracy in our centre, identifying with high sensitivity and 100% specificity cut-off values of 0.652 ng/mL for CSF p-NfH (P < .0001) and of 1261 pg/mL for NfL (P < .0001) in discriminating ALS from healthy controls. CSF neurofilaments were significantly correlated with ALS progression rate. Overall, CSF neurofilaments appear to reflect the burden of neurodegeneration in MND and represent reliable diagnostic and prognostic biomarkers in ALS.
Identifiants
pubmed: 33609080
doi: 10.1111/jcmm.16240
pmc: PMC8051694
doi:
Substances chimiques
Biomarkers
0
Neurofilament Proteins
0
neurofilament protein L
0
neurofilament protein H
108688-71-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3765-3771Subventions
Organisme : Italian Ministry of Health
Organisme : Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico
Informations de copyright
© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):12-20
pubmed: 26296871
J Neurol Sci. 1994 Apr;122(2):189-203
pubmed: 8021703
Eur J Neurol. 2012 Dec;19(12):1561-7
pubmed: 22680408
Neurology. 2015 Jun 2;84(22):2247-57
pubmed: 25934855
Ann Clin Transl Neurol. 2019 Apr 17;6(5):932-944
pubmed: 31139691
J Neurol. 2019 Sep;266(9):2129-2136
pubmed: 31123861
Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9
pubmed: 11464847
Annu Rev Neurosci. 1996;19:187-217
pubmed: 8833441
Nat Rev Neurol. 2015 Jun;11(6):351-9
pubmed: 25986506
Amyotroph Lateral Scler Frontotemporal Degener. 2017 Aug;18(5-6):397-403
pubmed: 28631955
J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):367-373
pubmed: 29054919
Ann Neurol. 2017 Dec;82(6):883-891
pubmed: 29149772
J Cell Mol Med. 2020 Mar;24(5):3034-3039
pubmed: 32032473
PLoS One. 2016 Oct 12;11(10):e0164625
pubmed: 27732645
Int J Mol Sci. 2019 Oct 30;20(21):
pubmed: 31671515
J Neurol. 2020 Jan;267(1):36-44
pubmed: 31552549
Clin Neurophysiol. 2008 Mar;119(3):497-503
pubmed: 18164242
Neurology. 2017 Jun 13;88(24):2302-2309
pubmed: 28500227
J Cell Mol Med. 2021 Apr;25(8):3765-3771
pubmed: 33609080
Int J Mol Sci. 2019 Aug 25;20(17):
pubmed: 31450699
J Neurol. 2018 Mar;265(3):510-521
pubmed: 29322259
Ann Clin Transl Neurol. 2015 Jul;2(7):748-55
pubmed: 26273687
J Neurol Neurosurg Psychiatry. 2011 Jul;82(7):740-6
pubmed: 21402743